IL151906A0 - Methods of therapy for non-hodgkin's lymphoma using a combination of an antibody to cd20 and interleukin-2 - Google Patents

Methods of therapy for non-hodgkin's lymphoma using a combination of an antibody to cd20 and interleukin-2

Info

Publication number
IL151906A0
IL151906A0 IL15190601A IL15190601A IL151906A0 IL 151906 A0 IL151906 A0 IL 151906A0 IL 15190601 A IL15190601 A IL 15190601A IL 15190601 A IL15190601 A IL 15190601A IL 151906 A0 IL151906 A0 IL 151906A0
Authority
IL
Israel
Prior art keywords
hodgkin
lymphoma
interleukin
antibody
therapy
Prior art date
Application number
IL15190601A
Other languages
English (en)
Original Assignee
Chiron Corp
Univ Rochester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp, Univ Rochester filed Critical Chiron Corp
Publication of IL151906A0 publication Critical patent/IL151906A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL15190601A 2000-03-24 2001-03-23 Methods of therapy for non-hodgkin's lymphoma using a combination of an antibody to cd20 and interleukin-2 IL151906A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19204700P 2000-03-24 2000-03-24
PCT/US2001/009413 WO2001072333A1 (en) 2000-03-24 2001-03-23 Methods of therapy for non-hodgkin's lymphoma using a combination_of an antibody to cd20 and interleuking-2

Publications (1)

Publication Number Publication Date
IL151906A0 true IL151906A0 (en) 2003-04-10

Family

ID=22708018

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15190601A IL151906A0 (en) 2000-03-24 2001-03-23 Methods of therapy for non-hodgkin's lymphoma using a combination of an antibody to cd20 and interleukin-2

Country Status (7)

Country Link
US (1) US20020009427A1 (bg)
EP (1) EP1267927A1 (bg)
JP (1) JP2003528155A (bg)
AU (1) AU2001247737A1 (bg)
CA (1) CA2404390A1 (bg)
IL (1) IL151906A0 (bg)
WO (1) WO2001072333A1 (bg)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7820161B1 (en) 1999-05-07 2010-10-26 Biogen Idec, Inc. Treatment of autoimmune diseases
IL150755A0 (en) * 2000-02-16 2003-02-12 Genentech Inc Uses of agonists and antagonists to modulate activity of tnf-related molecules
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
BR0211614A (pt) * 2001-08-03 2006-10-31 Genentech Inc polipeptìdeo tacis e br3 e empregos dos mesmos
AU2002362098A1 (en) * 2001-12-07 2003-06-23 Chiron Corporation Methods of therapy for non-hodgkin's lymphoma
CN100522999C (zh) 2002-02-14 2009-08-05 免疫医疗公司 抗cd20抗体及其融合蛋白和使用方法
US8287864B2 (en) * 2002-02-14 2012-10-16 Immunomedics, Inc. Structural variants of antibodies for improved therapeutic characteristics
CA2492447A1 (en) * 2002-07-25 2004-02-05 Genentech, Inc. Taci antibodies and uses thereof
EP2330130B1 (en) * 2002-10-17 2014-08-27 Genmab A/S Human monoclonal antibodies against CD20
AU2011202520C1 (en) * 2002-10-17 2016-02-18 Genmab A/S Human monoclonal antibodies against CD20
AU2015205832A1 (en) * 2002-10-17 2015-08-13 Genmab A/S Human Monoclonal Antibodies Against CD20
BRPI0316779B8 (pt) * 2002-12-16 2023-02-28 Genentech Inc Anticorpo anti-cd20 humano ou fragmento de ligação ao antígeno do mesmo, seus usos, composição, artigo manufaturado e formulação líquida
MXPA05010778A (es) 2003-04-09 2005-12-12 Genentech Inc Terapia para enfermedad autoinmune en un paciente con una respuesta inadecuada a un inhibidor tnf-alfa.
US20050163775A1 (en) * 2003-06-05 2005-07-28 Genentech, Inc. Combination therapy for B cell disorders
EP1629001A2 (en) 2003-06-05 2006-03-01 Genentech, Inc. Blys antagonists and uses thereof
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
WO2005117972A2 (en) * 2004-05-05 2005-12-15 Genentech, Inc. Preventing autoimmune disease by using an anti-cd20 antibody
JP2008501706A (ja) * 2004-06-04 2008-01-24 ジェネンテック・インコーポレーテッド 疾患の治療方法
EP1753455A2 (en) 2004-06-04 2007-02-21 Genentech, Inc. Method for treating multiple sclerosis
NZ552433A (en) * 2004-07-22 2009-10-30 Genentech Inc Method of treating sjogrenÆs syndrome
US20060110387A1 (en) * 2004-10-05 2006-05-25 Genentech, Inc. Method for treating vasculitis
KR20070104593A (ko) * 2005-01-13 2007-10-26 제넨테크, 인크. 치료 방법
DOP2006000029A (es) * 2005-02-07 2006-08-15 Genentech Inc Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
TW200714289A (en) * 2005-02-28 2007-04-16 Genentech Inc Treatment of bone disorders
US8475794B2 (en) 2005-04-06 2013-07-02 Ibc Pharmaceuticals, Inc. Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
US8349332B2 (en) 2005-04-06 2013-01-08 Ibc Pharmaceuticals, Inc. Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
AR053579A1 (es) * 2005-04-15 2007-05-09 Genentech Inc Tratamiento de la enfermedad inflamatoria intestinal (eii)
RU2007147426A (ru) * 2005-05-20 2009-06-27 Дженентек, Инк. (Us) Предварительная обработка биологического образца, взятого у индивидуума с аутоиммунным заболеванием
CA2616386A1 (en) 2005-07-25 2007-02-01 Trubion Pharmaceuticals Inc. Single dose use of cd20-specific binding molecules
DK2298815T3 (en) 2005-07-25 2015-06-15 Emergent Product Dev Seattle B-CELL REDUCTION USING CD37 SPECIFIC AND CD20 SPECIFIC BINDING MOLECULES
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
EP1952150B1 (en) * 2005-11-23 2016-12-14 Genentech, Inc. Methods and compositions related to b cell assays
SG172698A1 (en) 2006-06-12 2011-07-28 Trubion Pharmaceuticals Inc Single-chain multivalent binding proteins with effector function
MX354993B (es) 2007-07-09 2018-03-28 Genentech Inc Prevención de reducción de enlaces de disulfuro durante la producción recombinante de polipéptidos.
HUE030134T2 (en) 2007-10-16 2017-04-28 Zymogenetics Inc Combination of transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) and anti-CD20 agents for the treatment of autoimmune diseases
US7914785B2 (en) * 2008-01-02 2011-03-29 Bergen Teknologieverforing As B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
EP2077281A1 (en) 2008-01-02 2009-07-08 Bergen Teknologioverforing AS Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
ES2368700T3 (es) 2008-04-11 2011-11-21 Emergent Product Development Seattle, Llc Agente inmunoterapéutico para cd37 y combinación con un agente quimioterapéutico bifuncional del mismo.
CA2731255C (en) * 2008-07-21 2018-06-05 David M. Goldenberg Structural variants of antibodies for improved therapeutic characteristics
TW201438738A (zh) 2008-09-16 2014-10-16 Genentech Inc 治療進展型多發性硬化症之方法
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
US20110142836A1 (en) * 2009-01-02 2011-06-16 Olav Mella B-cell depleting agents for the treatment of chronic fatigue syndrome
KR20200111282A (ko) 2009-08-11 2020-09-28 제넨테크, 인크. 글루타민-비함유 세포 배양 배지에서의 단백질의 생성
CN102050879B (zh) * 2009-10-30 2014-02-19 上海抗体药物国家工程研究中心有限公司 抗人cd20人源化抗体、其制备方法及用途
US20110145072A1 (en) * 2009-12-15 2011-06-16 Bradley John Christiansen System and Method for Producing And Displaying Content Representing A Brand Persona
BR112012020102A2 (pt) 2010-02-10 2016-11-29 Immunogen Inc anticorpos cd20 e usos dos mesmos.
WO2013177187A2 (en) * 2012-05-22 2013-11-28 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-pk il-2 and therapeutic agents
CN107849096B (zh) 2015-05-30 2022-05-24 分子模板公司 去免疫化的志贺毒素a亚基支架和包含它们的细胞靶向分子
IL302486A (en) 2015-06-24 2023-06-01 Hoffmann La Roche Antibodies against the transnephrine receptor with adapted affinity
CA2999138C (en) 2015-09-21 2024-05-21 Aptevo Research And Development Llc Cd3 binding polypeptides
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
PE20231655A1 (es) 2015-10-02 2023-10-17 Hoffmann La Roche Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4931543A (en) * 1987-05-11 1990-06-05 Cetus Corporation Process for recovering microbially produced interleukin-2
EP1946775A3 (en) * 1998-08-11 2008-08-06 Biogen Idec Inc. Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibody

Also Published As

Publication number Publication date
CA2404390A1 (en) 2001-10-04
JP2003528155A (ja) 2003-09-24
AU2001247737A1 (en) 2001-10-08
EP1267927A1 (en) 2003-01-02
US20020009427A1 (en) 2002-01-24
WO2001072333A1 (en) 2001-10-04

Similar Documents

Publication Publication Date Title
IL151906A0 (en) Methods of therapy for non-hodgkin's lymphoma using a combination of an antibody to cd20 and interleukin-2
IL152896A0 (en) Cancer treatments by using a combination of an antibody against her2 and interleukin-2
IL206980A0 (en) Antibodies that bind human interleukin-18 and methods of making and using
EP1551875A4 (en) TAMPON PREPARATIONS FOR CONCENTRATING ANTIBODIES AND METHODS FOR USE THEREOF
YU28503A (sh) Humanizovana anti-lt-beta-r antitela
EP0703628A3 (en) MOSFET device with increased mobility and manufacturing method
IL143797A0 (en) Human monoclonal antibodies to cytotoxic t lymphocyte antigen 4
IL122370A (en) Monkey monoclonal antibodies to human B7 antigens and pharmaceutical compositions containing them
HUP9902327A3 (en) Humanized antibodies to human gp39, compositions containing and therapeutic use thereof
AP2000001983A0 (en) Antibodies to cd23 derivatives thereof and their therapeutic uses
EP1438467A4 (en) SILENCER MATERIAL FOR USE IN VEHICLES AND METHOD FOR THE PRODUCTION THEREOF
EP1011725A4 (en) HUMANIZED ANTIBODIES AGAINST GP39 HUMAN, COMPOSITIONS CONTAINING THESE ANTIBODIES AND THERAPEUTIC USE THEREOF
AU2002362098A8 (en) Methods of therapy for non-hodgkin's lymphoma
FR2813520B1 (fr) Dispositif de maintien corporel pour fauteuil verticalisateur et fauteuil en faisant application
EP1067199A4 (en) METHOD FOR COUNTING MICROORGANISMS AND DEVICE FOR PERFORMING SAID COUNT
AU2001256325A1 (en) Human and humanized fap-alpha-specific antibodies
AU2439602A (en) Pliable pad for collecting and absorbing liquids
AU2542295A (en) A disposable liquid-absorbent article, method and apparatus for its manufacture
LT96140A (en) The use of fibrin-specific antibody as an antithrombic agent
AU5688596A (en) Anti-cd14 antibodies for use in the induction of il-10 secre tion
GB2305370B (en) Device for depletion of leukocytes
GB0023654D0 (en) Device for administering doses of particulate material
HU0103040D0 (en) High - level source and it's application
AU2567599A (en) Anti-ccr1 antibodies and methods of use therefor
KR960030446U (ko) 인체의 체질감별용 힘측정기